Separately, BrainChild-01 (NCT03500991) utilizes a CAR T-cell targeting HER2 in children/young adult patients with r/r CNS tumors which are HER2-positive,136 while BrainChild-02 ((NCT03638167) utilizes an EGFR806-directed CAR T-cell among adolescent/young-adult patients with r/r CNS tumors expressing a tumor-specific untethered EGFR epitope.137. Here, EGFR is linked to central nervous system neoplasm.